Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma.

@article{Hulshof2000DoubleblindPS,
  title={Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma.},
  author={Maarten C C M Hulshof and J N Bouwes Bavinck and Wilma Bergman and A A Masclee and Lene Heickendorff and Ferdinand C. Breedveld and Ben A. C. Dijkmans},
  journal={Journal of the American Academy of Dermatology},
  year={2000},
  volume={43 6},
  pages={
          1017-23
        }
}
BACKGROUND Various treatments including corticosteroids, nonsteroidal anti-inflammatory drugs, D-penicillamine, interferon gamma, cyclosporine, and cytostatic drugs have been used with limited success in both morphea and systemic sclerosis (SSc). OBJECTIVE We investigated the effect of treatment with oral calcitriol in patients with localized or systemic scleroderma. METHODS A randomized, double-blind, placebo-controlled study of 9 months' duration with a 6-month follow-up was performed at… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

Update on morphea: part II. Outcome measures and treatment.

  • Journal of the American Academy of Dermatology
  • 2011
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

Robert Knobler, Pia Moinzadeh, +41 authors T. Krieg
  • Journal of the European Academy of Dermatology and Venereology : JEADV
  • 2017

Vitamin D and autoimmunity.

  • Scandinavian journal of rheumatology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND